Intended Audience
The Asia Pacific lancet and pen needles market is segmented on the basis of therapy, gauge, needle length, and end users.
On the basis of the therapy, the market is segmented into insulin, glucagon-like peptide-1 (GLP-1), growth hormones, and others.
On the basis of the gauge, the market is categorized into 17/18G, 21G, 23G, and others.
On the basis of the needle length, the market is segmented into 4mm, 8mm, 12mm, and others.
On the basis of the end users, the market is segmented into hospitals & clinics, medical institutions & research organizations, and others.
Some of the key players in the Asia Pacific lancet and pen needles market are:
February 2024: Eli Lilly hopes to launch its bestselling antidiabetic medication, specified as Mounjaro (tripeptide), which will be around early next year. Indian health regulatory bodies, including Mounjaro, are currently investigating this.
June 2023: Shilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited (SML), was granted marketing authorization for its Adalimumab injection in prefilled syringe (PFS). It is a biosimilar for high concentration adalimumab formulation for rheumatoid arthritis treatment.
During CPHI Japan 2023, SHL Medical introduced Molly modular platform autoinjectors with pre-installed Needle Isolation Technology (NIT).
September 2022: The Microsoft and Novo Nordisk partnership was announced in September 2022, merging computational services, cloud computing AI and knowledge thirst in drug development as well as Novo Nordisk’s data engineering services.
On September 2022, Novo Nordisk acquired Forma Therapeutics. That company is committed to changing lives of Sickle cell disease (SCD) patients among other rare blood diseases.
| Report Attribute/Metric | Details |
| Market Size 2030 | Â USD 3.45 Billion 2032 |
| Compound Annual Growth Rate (CAGR) | 12.67% 2032 |
| Base Year | 2021 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, technology, application, and end-users. |
| Geographies Covered | Americas, Europe, Asia Pacific and the Middle East and Africa |
| Countries Covered | China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific |
| Key Companies Profiled | BD. (U.S.), Novo Nordisk A/S (Europe), Ypsomed (Europe), B. Braun Melsungen AG (Europe), HTL-STREFA (Europe), Terumo Corporation (Asia Pacific), Artsana S.p.A. (Europe), Owen Mumford Ltd. (Europe). |
| Key Market Opportunities | Key market opportunities in the Asia Pacific lancet and pen needles market include rising diabetes prevalence, increasing healthcare expenditure, and growing awareness about advanced diabetes management technologies. |
| Key Market Dynamics | The key market dynamics for the Asia Pacific lancet and pen needles market include rising diabetes prevalence, increasing adoption of self-monitoring blood glucose devices, technological advancements in needle design, growing awareness and patient education, and expanding healthcare infrastructure. |
Asia Pacific Lancet Pen Needels Market Highlights:
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
